Quantcast

Latest Cadence Pharmaceuticals Inc. Stories

2010-05-14 15:45:00

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV(TM) (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010. "If approved, OFIRMEV will be the only intravenous (IV) non-opioid,...

2010-05-06 15:01:00

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2010. As announced on May 5, 2010, the company re-submitted its New Drug Application, or NDA, for its investigational product candidate, OFIRMEV(TM) (acetaminophen injection)...

2010-05-05 06:30:00

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, OFIRMEV(TM) (acetaminophen) injection, for the treatment of pain and fever in adults and children. The NDA for OFIRMEV was resubmitted on May 4, 2010. The FDA will determine the type of resubmission (Class 1 or Class 2) and resulting review...

2010-04-29 15:00:00

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2010 financial results after the market closes on Thursday, May 6, 2010. Cadence management will host a conference call and live webcast to discuss the financial results...

2010-04-27 15:00:00

SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present a corporate overview at the following investment conferences: Deutsche Bank's 35th Annual Health Care Conference at the InterContinental Hotel in Boston...

2010-04-19 06:30:00

SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that, based on feedback received during a meeting with the U.S. Food and Drug Administration (FDA) on April 16, 2010, it plans to re-submit a New Drug Application (NDA) for its investigational product candidate, OFIRMEV(TM) (acetaminophen) injection, within the next 30 days. The April 16 meeting was a Type A meeting held among the FDA, Cadence, and its third party manufacturer to...

2010-03-29 15:00:00

SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today the appointment of Michael L. Eagle to the company's board of directors. "We are very pleased to welcome Mike Eagle to our board of directors," stated Cam Garner, Chairman of Cadence. "With more than 35 years of experience in executive management and engineering, primarily focused on the manufacture of pharmaceutical products and medical devices, Mike will be an excellent addition to...

2010-03-15 15:00:00

SAN DIEGO, March 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the fourth quarter and year ended December 31, 2009. During 2009, Cadence completed its clinical development program and submitted a New Drug Application (NDA) for its investigational product candidate,...

2010-03-08 15:30:00

SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2009 financial results after the market closes on Monday, March 15, 2010. Cadence management will host a conference call and live webcast to discuss the...

2010-03-02 15:30:00

SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, March 9, 2010 at 11:05am Eastern Time (8:05am Pacific Time) during the Cowen and Company 30th Annual Health Care...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related